NASDAQ: AYTUAytu Biopharma Inc Stock
$2.16+0.00 (+0%)
Updated Jul 2, 2026
AYTU Price
$2.16
Fair Value Price
N/A
Market Cap
$23.18M
52 Week Low
$1.65
52 Week High
$3.07
P/E
-0.47x
P/B
0.66x
P/S
0.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$56.60M
Earnings
-$34.06M
Gross Margin
64.8%
Operating Margin
-55.42%
Profit Margin
-60.2%
Debt to Equity
2.18
Operating Cash Flow
$2M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AYTU Overview
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AYTU's potential to beat the market
- AYTU doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
AYTU
RankedUnranked of 51
RankedUnranked of 51
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $174.26 | A | |
| $39.80 | A | |
| $4.33 | A |
Be the first to know about important AYTU news, forecast changes, insider trades & much more!
AYTU News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AYTU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AYTU is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AYTU is good value based on its book value relative to its share price (0.66x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.59x)
P/B vs Industry Valuation
AYTU is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AYTU due diligence checks available for Premium users.
Valuation
AYTU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.47x
Industry
-5.68x
Market
8.54x
AYTU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.66x
Industry
1.59x
AYTU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AYTU's financial health
Profit margin
Revenue
$12.4M
Net Income
-$5.6M
Profit Margin
-45.3%
AYTU's Earnings (EBIT) of -$31.37M... subscribe to Premium to read more.
Interest Coverage Financials
AYTU's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$111.7M
Liabilities
$76.5M
Debt to equity
2.18
AYTU's short-term assets ($67.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AYTU's short-term assets ($67.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AYTU's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AYTU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
$0.0
Financing
$872.0k
AYTU's operating cash flow ($1.68M)... subscribe to Premium to read more.
Debt Coverage Financials
AYTU vs Pharmaceutical Stocks
Aytu Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.